奈他地尔二甲磺酸盐 | 1422144-42-0

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 奈他地尔二甲磺酸盐
• 中文别名: 奈他地尔 二甲磺酸盐；奈妥舒迪
• 英文名称: Netarsudil Mesylate
• 英文别名: [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate;methanesulfonic acid
• CAS: 1422144-42-0
• 化学式: C30H35N3O9S2
• 分子量: 645.7
• InChiKey: QQDRLKRHJOAQDC-FBHGDYMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  44
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  220
• 氢给体数：
  4
• 氢受体数：
  11

文献信息

• [EN] COMBINATION THERAPY<br/>[FR] TRAITEMENT COMBINÉ
  申请人：AERIE PHARMACEUTICALS INC

  公开号：WO2014144781A1

  公开（公告）日：2014-09-18

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼压的化合物和组合物。组合物可能包括异喹啉化合物和一种前列腺素或前列腺素类似物。本文描述的化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的化合物，以及异喹啉化合物和前列腺素游离酸一起形成盐的化合物。
• PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20170204065A1

  公开（公告）日：2017-07-20

  Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

  本文描述了一些合成特定化合物的过程，这些化合物可用于治疗一些疾病，例如眼病，如青光眼和眼压增高，适用于治疗患者。
• COMBINATION THERAPY
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20160243105A1

  公开（公告）日：2016-08-25

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼内压力的化合物和组合物。组合物可以包括异喹啉化合物和前列腺素或前列腺素类似物。所描述的化合物包括那些异喹啉化合物与前列腺素或前列腺素类似物共价键结合的化合物，以及异喹啉化合物和前列腺素自由酸一起形成盐的化合物。
• COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：EP3811943A1

  公开（公告）日：2021-04-28

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼内压的化合物和组合物。 组合物可包括异喹啉化合物和前列腺素或前列腺素类似物。 本文所述的化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的化合物，以及异喹啉化合物和前列腺素游离酸共同形成盐的化合物。
• Combination therapy
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US10568878B2

  公开（公告）日：2020-02-25

  Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

  本文描述了用于治疗青光眼和/或降低眼内压的化合物和组合物。组合物可包括异喹啉化合物和前列腺素或前列腺素类似物。本文所述的化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的化合物，以及异喹啉化合物和前列腺素游离酸共同形成盐的化合物。